Elena-Cristina Gheara

Ms. Elena-Cristina Gheara

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IBIoana Brie
Ioana Brie
MPMaria Ida Perde-Schrepler
Maria Ida Perde-Schrepler
PVPiroska Virág
Piroska Virág
CBCristina Balan
Cristina Balan
EGElena-Cristina Gheara
Elena-Cristina Gheara
DMDaniela Laura Martin
Daniela Laura Martin
The intersection of radiotherapy and immunology has emerged as a highly promising frontier: localized radiotherapy can act as an in-situ vaccine, triggering prompt systemic anti-tumor responses. Carbon ion radiotherapy (CIRT) outperforms conventional photon radiotherapy (XRT) by delivering a highly concentrated dose to the target volume while minimizing collateral damage to adjacent healthy structures and preserving peripheral immune tissues. Emerging preclinical and clinical data indicate that CIRT possesses ex-traordinary immunomodulatory potential. High-LET carbon ion irradiation strongly drives immunogenic cell death (ICD), promotes mature dendritic cell antigen presentation, and strongly upregulates the cGAS–STING signaling cascade, shifting the TME from a "cold" immunosuppressive state to a "hot" immunostimulatory environment. Recent find-ings also show that carbon ions potently trigger non-apoptotic cell death modalities, fer-roptosis, necroptosis, and autophagy, which amplify ICD. When combined with IT, this triggers a potent synergistic effect that targets both local tumor recurrence and distant me-tastases. However, clinical translation faces critical issues, including patient selection and optimal dosing and scheduling. This review synthesizes key preclinical breakthroughs and emerging clinical data on CIRT combined with IT, exploring the molecular mecha-nisms underlying the synergy of this combination. We also discuss perspectives and fu-ture directions needed to optimize this promising therapeutic strategy.

6 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Daniel UngureanuDaniel Ungureanu
Daniel Ungureanu
PVPiroska Virág
Piroska Virág
Brindusa TiperciucBrindusa Tiperciuc
Brindusa Tiperciuc
Radu TamaianRadu Tamaian
Radu Tamaian
IBIoana Brie
Ioana Brie
OOOvidiu Oniga
Ovidiu Oniga
Background/Objectives: Combining heterocyclic fragments provides a strategy for developing compounds for exploratory anticancer evaluation. This study aimed to synthesize and characterize five thiazolyl-methylthio-1,3,4-thiadiazolyl-quinazolin-4(3H)-one compounds (5a–e), assess their properties in silico, and investigate the selected ones for cytotoxicity and their effects on irradiation-associated DNA lesions. Methods: Structures were characterized by IR, HRMS, and 1H- and 13C-NMR spectroscopy. Computational studies included physicochemical and ADMETox predictions, multi-platform target prediction, and molecular docking to A2A, Erβ, and CDK5. Compounds 5a and 5b were evaluated for cytotoxicity and cell-death profiles on one colorectal cancer (CRC) cell line (HT-29), two breast cancer (BC) cell lines (MCF-7 and MDA-MB-231), and one healthy fibroblast cell line (BJ), using cisplatin (Cis) as a reference. DNA lesions were assessed by the Comet assay in both breast cancer models before, immediately after, and 24 h after 4 Gy irradiation. Results: Compounds 5a–e were obtained in yields of 45.17–83.27%. Compounds 5a and 5b had lower 24-h IC50 values than cisplatin in MCF-7 cells, but higher values in the other tested cell lines. Compound 5b showed higher selectivity indexes than both 5a and cisplatin across the cancer models, although its values of 1.14–1.34 indicated modest selectivity. Cell-death profiles differed between treatments, with larger necrotic fractions following 5a or 5b treatment in MCF-7 cells. Both compounds were associated with higher post-irradiation lesion scores than untreated irradiated controls. Scores increased further at 24 h in MCF-7 cells but decreased in MDA-MB-231 (triple-negative) cells. Pre-irradiation scores were also elevated in treated MCF-7 cells. Computational profiling identified comparatively more favorable predicted solubility for 5a and 5b. Cross-platform ADMET comparison consistently indicated low Caco-2 permeability, CYP3A4 inhibition, potential liver-injury risk, and high plasma–protein binding, while several absorption, transporter, and safety endpoints remained discordant. Target predictions showed weak cross-platform convergence. Docking provided the strongest, although moderate, structural support for A2A binding by 5a–d. Conclusions: The findings support further investigation of 5a and 5b, particularly their effects on irradiation-associated DNA lesions. Priorities include improving potency and selectivity, validating in silico predictions, and evaluating radiosensitizing potential through clonogenic survival studies.